drugset / Trial / NCT04667533

Desidustat in the Treatment of Chemotherapy Induced Anemia

NCT04667533

Phase 1 Completed 24 enrolled Zydus Lifesciences Limited
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, Open-label, Single Dose, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Desidustat for treatment of anemia in patients receiving chemotherapy.

Timeline

Start
2020-11-11
Primary completion
2022-03-27
Completion
2022-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Desidustat Small molecule 100 mg
Subject Desidustat Small molecule 150 mg
Subject Desidustat Small molecule 200 mg